Reformed pharmaceutical regulation across India’s drug landscape
Extra regulatory scrutiny is highly necessary when attempting to keep pace with the rapid biotechnological development in India.
Comment & Opinion
Updated UK guidance for finerenone introduces new treatment for HF patients
Repligen’s deal for BioLife Solutions indicates shift to manufacturing integration
FDA approval of mFLUSIVA highlights Moderna’s position in mRNA market
Rethinking sterile product development for manufacturing success
What will health and social care look like under Andy Burnham?
European drug manufacturers under threat from proposed US supply chain bill
Cell and gene therapy manufacturers turn to specialist automation partners
